VIDEO: Seladelpar may improve transplant-free survival in primary biliary cholangitis
Click Here to Manage Email Alerts
In a Healio video exclusive, Bettina E. Hansen, MSc, PhD, discusses improvement in transplant-free survival in patients treated with seladelpar for primary biliary cholangitis.
Hansen and colleagues conducted a long-term, open-label study and used the GLOBE score, a risk assessment tool, to determine the effect of oral seladelpar on transplant-free survival in patients with PBC.
“We were able to estimate an improved GLOBE score over time for 2 years,” Hansen, a senior biostatistician at the Toronto Center for Liver Disease and associate professor at the University of Toronto, said. “This translated again into improvement of transplant-free survival of about 7% at 10 years and more than 10% at 15 years.”
Collapse
Hansen BE, et al. Abstract 323. Presented at: Digestive Disease Week; May 21-24, 2022; San Diego (hybrid meeting).
Read more about
Click Here to Manage Email Alerts